This is a challenging pathogen, requiring pharmacokinetic and pharmacodynamic considerations; the recent FDA approval of sulbactam-durlobactam offers new hope.
Walaiporn Wangchinda, MD
Advertisement
Wangchinda is a research fellow at the University of Michigan College of Pharmacy in Ann Arbor and an infectious diseases physician at Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Articles by Walaiporn Wangchinda, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Contagion Live
1
Phase 3 Trial Confirms Superior Efficacy of Oral Pritelivir for Refractory HSV in Immunocompromised Patients
2
UCF Team Advances Low-Cost Multiplex RNA Test for HIV, HBV, and HCV
3
Developing the Next Generation of Rifamycins for Non-TB Mycobacteria in a Postantibiotic Era
4
